Atidortoxumab/Berlimatoxumab

N/A

Report date: 2022/11/12 16:46:38

Base Information

Drug NameAtidortoxumab/Berlimatoxumab
Drug Alias NameASN-100ASN-1/ASN-2
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-hly
TargetsAlpha-hemolysin
Therapy Area/IndicationsStaphylococcal Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes BerlimatoxumabAtidortoxumab
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesArsanis Biosciences
China Registration ClassN/A

Develop Information

Active CompaniesArsanis Biosciences
Inactive CompaniesN/A
Active IndicationsStaphylococcal Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A